Clinical Trial

QoLIDia: Quality of Life in Cancer Patients With Diabetes During Immunotherapy

Study acronym: QoLIDia
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to see how type 2 diabetes affects quality of life in cancer patients receiving immunotherapy. We want to know if patients with diabetes have a greater decline in quality of life over six months compared to those without. The main question we aim to answer is: \- How does quality of life change over six months in patients with versus without diabetes? Participants will complete quality-of-life surveys at the start, then at 3 and 6 months. This will help us see if diabetes adds extra challenges during cancer treatment
Trial Details
NCT Number NCT07466212
Lead Sponsor Odense University Hospital
Conditions Cancer, Type 2 Diabetes
Enrollment 920 participants
Start Date 2026-03-10
Primary Completion 2027-10-01 (estimated)
Study Completion 2027-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-12